2015 Regulatory Trends in the US Pharma/Biotech Industry
DUBLIN, Apr. 10, 2015 /PRNewswire/ --Research and Markets
(http://www.researchandmarkets.com/research/t8g4v8/regulatory_trends) has announced the addition of the "Regulatory Trends in the US Pharma/Biotech Industry " report to their offering.
This market insight provides an analysis of the regulatory trends occurring in the US pharma/biotech industry for 2014. Included in this deliverable is an analysis of the new molecular entities (NME) approved by the US Food and Drug Administration in 2014 and predictions for 2015. Trends are showing that the US Food and Drug Administration is moving towards greater efficiency and expedited review periods, which will lead to faster access to care.
Key Topics Covered:
1. Regulatory Trends in the US Pharma/Biotech Industry
2. Executive Summary
- Key Findings
3. Analysis of 2014 New Molecular Entities US FDA Filings and Approvals
- NME Trends Show a Significant Increase in Regulatory Filings and Approvals
- Increase in Orphan Drug Approvals
- Increase in First-in-class Designation
- Most Approved NMEs Evaluated as an Expedited Review
- High Number of First Cycle Approval Continues
- Oral Therapies Continue Dominating the Pharma/Biotech Industry
- NMEs Approved in 2014
4. Predictions for 2015
For more information visit http://www.researchandmarkets.com/research/t8g4v8/regulatory_trends
Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net
Share this article